CONGRESS|#EHA2021|@Cristin53875581, presented data on selinexor containing triplets in MM pts treated previously with alpha CD38mAB, triple class refractory. improved tolerance, effectiveness & higher OS was observed compared to previous therapies. #mmsm, #myeloma, @DukeCancer pic.twitter.com/Tsokem9COB
— Multiple Myeloma Hub (@MM_Hub) June 13, 2021